Preview

Rational Pharmacotherapy in Cardiology

Advanced search

DYNAMICS OF THE HEART RATE VARIABILITY IN PATIENTS WITH ATRIAL FIBRILLATION DURING ATORVASTATIN THERAPY

https://doi.org/10.20996/1819-6446-2008-4-3-33-38

Full Text:

Abstract

Aim. To evaluate the heart rate variability (HRV) in patients with ischemic heart disease (IHD) and paroxysmal atrial fibrillation (AF) during atorvastatin therapy.

Material and methods. 60 patients with IHD and paroxysmal AF were included in the study. Patients were divided into two groups – control group (basic antiarrhythmic therapy) and second group (basic antiarrhythmic therapy and atorvastatin (Liptonorm, Pharmstandart, Russia) 10mg/day). HRV was compared before and after 3 months of therapy in both groups.

Results. Liptonorm significantly improved HRV indices in comparison with basic therapy alone: RMSSD increased on 33% (р <0,02), total power (TP) of spectrum on 28% (р <0,03) and high frequency (HF) component on 53 % (р <0,01).

Conclusion. Liptonorm therapy improves autonomic balance in patients with IHD and paroxysmal AF.

About the Authors

E. S. Kozlova
Volgograd State Medical University Volgograd Regional Clinical Cardiology Centre
Russian Federation


E. E. Galaktionova
Volgograd State Medical University Volgograd Regional Clinical Cardiology Centre
Russian Federation


F. A. Nemchuk
Volgograd State Medical University Volgograd Regional Clinical Cardiology Centre
Russian Federation


Yu. M. Lopatin
Volgograd State Medical University Volgograd Regional Clinical Cardiology Centre
Russian Federation


References

1. Жемайтите Д., Тельксниса Л., редакторы. Анализ сердечного ритма. Вильнюс: Мокслас;1982.

2. Баевский Р.М., Кириллов О.И., Клецкин С.З. Математический анализ изменений сердечного ритма при стрессе. М: Наука; 1984.

3. Вейн А.М., редактор. Заболевания вегетативной нервной системы. Руководство для врачей. М.: Медицина; 1991.

4. Коркушко О.В., Писарчук А.В., Шатило В.Б. и др. Анализ вариабельности ритма сердца в клинической практике. Киев; 2002.

5. Киселев А. Р., Гриднев В. И., Колижирина О. М., Киричук В. Ф. Использование показателей чувствительности и устойчивости низкочастотной компоненты спектра вариабельности сердечного ритма в клинической практике. Росс кардиол журн 2004;(4):18-23.

6. Баевский, Р.М., Иванов, Г.Г., Чирейкин, Л.В. Анализ вариабельности сердечного ритма при использовании различных электрокардиографических систем (часть 1). Вестник аритмологии 2002;(24):65-87.

7. Довгалевский П.Я., Рыбак О.К., Фурман Н.В. Показатели вариабельности ритма сердца у больных ишемической болезнью сердца в зависимости от тяжести атеросклероза коронарных артерий (по данным селективной коронарографии) и функционального класса стенокардии. Кардиология 2002;(9):16-21.

8. Амосова Е.Н., Бойчак М.П., Сидорова Л.Л. Вариабельность сердечного ритма и ее взаимосвязь с функциональным состоянием миокарда левого желудочка у больных ишемической болезнью сердца с начальной сердечной недостаточностью. Сердце i судини 2003;(4): 88-95.

9. Lucini D., Norbiato G., Clerici M. et al. Hemodynamic and autonomic adjustments to real life stress conditions in humans. Hypertension 2002;39:184-8.

10. Bigger J.T., Kleiger R.E., Fleiss J.L. et al. and the Multicenter Post-Infarction Research Group. Component of heart rate variability measured during healing of acute myocardial infarction. Am J Cardiol 1988;61:208-15.

11. Kleiger R.E., Miller J.P., Bigger J.T. et al. and the Multicenter Post-Infarction Reseach Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256-62.

12. Мамий В.И. Оценка функционального состояния. Вариабельность ритма сердца и вегетатив- ный баланс. СПб.:; 2002.

13. Ewing D.J., Clarce D.F. Autonomic neuropathy: its diagnosis and prognosis. Clin Endocrin Metabol 1986;15 (4):855-888.

14. Young-Xu Y., Jabbour S., Goldberg R. et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003;92(12):1379–83.

15. Siu C. W., Lau C. P., Tse H.F. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003;92(11):1343-5.

16. Kumagai K., Nakashima H., Saku K. The HMG- CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004;62:105–11.

17. Tveil A., Grundtvig M., Gundersen T. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2004;93:780-2.

18. Hanna IR, Heeke B, Bush H, et al. Lipid-lowering drug use in associated with reduced the prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006;3:881–6.

19. Nakao K., Shibata R., Fukae S. et al. Statin drugs suppress the incidence of the prolonged and fractionated right atrial electrogramms in patients with idiopathic paroxysmal atrial fibrillation. Eur Heart J 2006; (Abstract Suppl.):882.

20. Patti G., Chello M., Candura D. et al. A randomized trial of atorvastatin for reduction of post-operative atrial fibrillation in patients undergoing cardiac surgery. Circulation 2006;114:1455–61.

21. Patel A.A., White C.M., Shah S.A. et al. The relationship between statin use and atrial fibrillation. Curr Med Res Opin 2007;23(5):1177-85.

22. Fauchier L., Pierre B., de Labriolle A. et al. Antiarrhythmic effect of statin therapy and atrial fibrillation. J Am Coll Cardiol 2008;51:828 – 35.

23. Кушаковский М.С. Аритмии сердца: Руководство для врачей. СПб: Гиппократ; 1992.

24. Васюк Ю.А., Атрощенко Е.С., Ющук Е.Н. Плейотропные эффекты статинов – данные фундаментальных исследований. Сердце 2006;5(5):228–37.

25. Pliquett R.U., Cornish K.G., Peuler J.D.et.al. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003;107(19):2493-8.

26. Pliquett R.U., Cornish K.G., Zucker I.H. Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol 2003;95(2):700-4.

27. Макаров Л.М. Холтеровское мониторирование. М: Медпрактика; 2000.

28. Malik M., Bigger J.T., Camm J.A. Heart rate variability, standards of measurement, physiological interpretation and clinical use. Task force of the European Society of Cardiolody and the North American Society of pacing and electrophysiolody. Eur Heart J 1996;17:354-81.

29. Рябыкина Г.В., Соболев А.В. Вариабельность ритма сердца. М: Медицина; 1998.

30. Березный Е.А., Рубин А.М. Практическая кардиоритмография. СПб: НПП «Нео»; 1997. С. 15- 17.

31. Земцовский Э.В., Тихоненко В.М., Рева С.В. Функциональная диагностика состояния вегетативной нервной системы. СПб: НПП–Инкарт; 2004.

32. Nickenig G., Baumer A.T., Temur Y. et al. Statin- sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999;100(21):2131-4.

33. Ito M., Adachi T., Pimentel D.R. et al. Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism. Circulation 2004;110(4):412-8.

34. Horiuchi M., Cui T.X., Li Z. et al. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 2003;107(1):106-12.

35. Saijonmaa O., Nyman T., Stewen P. et al. Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells. Am J Physiol Heart Circ Physiol 2004;286(6):2096-102.

36. Van der Harst P., Wagenaar L.J., Buikema H. et al. Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease. Am J Cardiol 2005;96(10):1361-4.

37. Riahi S., Christensen J.H., Toft E. et.al. HGM-CoA reductase inhibitors improve heart rate variability in patients with a previous myocardial infarction. Pharmacol Res 2002;45(6):479-83.

38. Katircibasi M.T., Canatar T., Kocum H.T. et al. Decreased heart rate recovery in patients with heart failure: effect of fluvastatin therapy. Int Heart J 2005;46(5):845-54.

39. Krum H., Bailey M., Meyer W. et al. Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: results of CIBIS II. Cardiology 2007;108(1):28-34.

40. Melenovsky V., Wichterle D., Simek J. et al. Effect of atorvastatin and fenofibrate on autonomic tone in subject with combined hyperlipidemia. Am J Cardiol 2003;92(3):337-41.

41. Hamaad A., Sosin M., Lip G.Y. et al. Short-term adjuvant atorvastatin improves frequency domain indiced of heart rate variability in stable systolic heart failure. Cardiovasc Drugs Ther 2005;19(3):183- 7.

42. Welzig CM, Shin DG, Park HJ, et.al. Lipid lowering by pravastatin increases parasympathetic modulation of heart rate. Circulation 2003;108(21):2743-6.

43. Vrtovec B., Okrajsek R., Golicnik A. et al. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QT interval duration in patients with advanced chronic heart failure. J Card Fail 2005;11(9):684-90.

44. Канорский С.Г., Скибицкий В.В., Кудряшов Е.А. Новые возможности оценки профилактического эффекта антиаритмических препаратов у больных с пароксизмальной фибрилляцией пред- сердий. Кардиология 1997;37(1):42-46.

45. Hohnloser S.H., Klingenheben T., Zabel M., Just H. Effect of sotalol on heart rate variability assessed by Holter monitoring in patients with ventricular arrhythmias. Am J Cardiol 1993;72(4):67A-71A.


For citation:


Kozlova E.S., Galaktionova E.E., Nemchuk F.A., Lopatin Yu.M. DYNAMICS OF THE HEART RATE VARIABILITY IN PATIENTS WITH ATRIAL FIBRILLATION DURING ATORVASTATIN THERAPY. Rational Pharmacotherapy in Cardiology. 2008;4(3):33-38. (In Russ.) https://doi.org/10.20996/1819-6446-2008-4-3-33-38

Views: 352


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)